PfizerMEX:PFE -0.22%67 Return-on-Tangible-Asset is 12.90% as of Mar. 2026, which is 6% below its 10-year median of 13.75. GuruFocus rates MEX:PFE with a GF Score™ of 67/100 and a GF Value™ of MXN456.62 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Pfizer ranks better than 74.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pfizer's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN193,815 Mil. Pfizer's average total tangible assets for the quarter that ended in Mar. 2026 was MXN1,502,949 Mil. Therefore, Pfizer's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 12.90%.
The historical rank and industry rank for Pfizer's Return-on-Tangible-Asset or its related term are showing as below:
MEX:PFE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.16 Med: 13.75 Max: 32.38
Current: 8.81
During the past 13 years, Pfizer's highest Return-on-Tangible-Asset was 32.38%. The lowest was 2.16%. And the median was 13.75%.
MEX:PFE's Return-on-Tangible-Asset is ranked better than 74.73% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.17
vs MEX:PFE: 8.81
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Pfizer Return-on-Tangible-Asset Related Terms
Pfizer Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Pfizer's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PFE vs GILD, BMY, AMGN: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Pfizer's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Pfizer's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.90% mean?
Pfizer (MEX:PFE) has a Return-on-Tangible-Asset of 12.90% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pfizer and its competitors. This is near median its historical median of 13.75. Over the past decade, Pfizer's Return-on-Tangible-Asset has ranged from 2.16 to 32.38. According to the industry distribution chart, Pfizer ranks #254 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is Pfizer's Return-on-Tangible-Asset too high?
Pfizer's current Return-on-Tangible-Asset of 12.90% is near median its 10-year median of 13.75. Over the past 10 years, this metric has ranged from a low of 2.16 to a high of 32.38. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.17. Pfizer's value of 12.90% is 306.9% above this industry median. Based on the distribution chart, Pfizer ranks #254 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pfizer has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Return-on-Tangible-Asset compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #254 out of 1005 companies for Return-on-Tangible-Asset. This puts Pfizer in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.17. Pfizer's value of 12.90% is 306.9% above this benchmark. Historically, Pfizer's own Return-on-Tangible-Asset has ranged from 2.16 to 32.38 over the past decade. While the company's 10-year median is 13.75 vs. the industry median of 3.17, Pfizer has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.17, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pfizer's current Return-on-Tangible-Asset of 12.90% is 306.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pfizer and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pfizer's current Return-on-Tangible-Asset is 12.90%, which is near median its own 10-year median of 13.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (MEX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is MXN456.62, compared to a current price of MXN423.06 — trading 7.3% below its estimated fair value. The current Return-on-Tangible-Asset is 12.90%, which is near median its 10-year median of 13.75 and 306.9% above the Drug Manufacturers industry median of 3.17. Pfizer's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pfizer (MEX:PFE), the current Return-on-Tangible-Asset is 12.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (MEX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of MXN423.06 is trading 7.3% below its estimated GF Value™ of MXN456.62.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for MEX:PFE:
Return-on-Tangible-Asset: 12.90% (near median its 10-year median of 13.75)
GF Value™: MXN456.62 vs. price of MXN423.06 (7.3% below fair value)
Industry Position: 306.9% above the Drug Manufacturers median (#254 of 1005)
No single metric tells the full story. See the MEX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
67GF Score
Get the complete analysis for MEX:PFE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PFE has been successfully added to your 
